AMGN Stock Recent News
AMGN LATEST HEADLINES
THOUSAND OAKS, Calif. , Aug. 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the third quarter of 2025.
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing globally, the future of gene therapy, changes at FDA, and more.
CNBC's Joe Kernen reports on the latest news.
THOUSAND OAKS, Calif. , July 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2025 financial results on Tuesday, August 5, 2025, after the close of the U.S. financial markets.
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House said on Thursday.
President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a controversial policy that aims to slash drug costs by tying the prices of some medicine in the U.S. to the significantly lower ones abroad.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Amgen (AMGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
AMGN eyes another earnings beat as strong drug volumes offset pricing pressure and biosimilar headwinds.
Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.